Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor Relations Marjorie Green - SVP, Head of Oncology Clinical Development Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this, meeting. I'm Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America.
US FDA expands use of Merck's cancer drug for adrenal gland tumors
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.
Merck Animal Health announces $895 million investment in Kansas
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda
The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports
U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall Street Journal reported on Tuesday.
Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks
The two companies have been talking for months about a deal
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President of Merck Research Labs Conference Call Participants Geoff Meacham - Citi Tim Anderson - Bank of America Luisa Hector - Berenberg Vamil Divan - Guggenheim Securities Chris Schott - JPMorgan James Shin - Deutsche Bank Steve Scala - TD Cowen Alex Hammond - Wolfe Research Umer Raffat - Evercore Akash Tewari - Jefferies Mohit Bansal - Wells Fargo Operator Thank you for standing by. Welcome to the Merck & Company Incorporated Rahway, New Jersey, USA Quarter One Sales and Earnings Conference Call.
Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
